# DEA Control of Synthetic Ketamine Analogs: 2-Fluorodeschloroketamine Scheduling > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/ > **Published:** 2026-06-12T08:26:07-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:04:58-04:00 > **Clinical Summary:** Explore DEA synthetic ketamine analog control with the temporary Schedule I placement of 2-fluorodeschloroketamine and its clinical and regulatory implications. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesSchedule_I2-Fluorodeschloroketaminestate_regulation Clinical Summary The Drug Enforcement Administration has temporarily placed 2-fluorodeschloroketamine (2-FDCK), a synthetic ketamine analog, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, classifying it alongside cannabis and other drugs with no currently accepted medical use. This regulatory action addresses the emergence of 2-FDCK as a novel psychoactive substance in illicit drug markets, where it has been marketed as a legal alternative to ketamine and other controlled dissociatives. While this substance is not cannabis-related, the scheduling action reflects the broader [regulatory framework](https://cedclinic.com/tennessee-cannabis-patient-access-legislative-updates/) that clinicians must understand when considering the legal status of psychoactive compounds and their derivatives. For cannabis clinicians specifically, this underscores how rapidly the controlled substance landscape evolves and how novel analogs of established drugs—whether ketamine or cannabinoids—may face sudden legal restrictions that affect both prescribing decisions and [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to treatments. Clinicians should remain informed about DEA scheduling updates and advise patients to verify the legal status of any psychoactive substances they use, as temporary and emergency scheduling can change the legal landscape quickly. The practical takeaway is that clinicians should monitor DEA notices and regulatory updates to ensure their prescribing and [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/) remain aligned with current controlled substance law. Clinical Perspective 🧠 The DEA’s temporary placement of 2-fluorodeschloroketamine (2-FDCK) into Schedule I reflects ongoing regulatory challenges in managing novel synthetic drugs that circumvent existing controlled substance laws. As a ketamine analog, 2-FDCK raises clinical concerns similar to other dissociative compounds, including potential for abuse and adverse psychiatric or neurological effects, yet the evidence base on human safety and efficacy remains extremely limited since it has not undergone [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/). Clinicians should be aware that patients may seek or encounter these emerging substances as alternatives to regulated medications or illicit drugs, sometimes believing them to be legal or safer options. The rapid pace of analog creation outstripping regulatory response means that standard screening and toxicology protocols may not detect these agents, potentially complicating clinical assessment of patients presenting with dissociative symptoms or behavioral changes. In practice, a heightened index of suspicion for novel synthetic drug use 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+2-Fluorodeschloroketamine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+2-Fluorodeschloroketamine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/) - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) - [DEA Places Four Synthetic Cannabinoids in Schedule I](https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) Detailed analysis of FDA-approved marijuana products rescheduled from Schedule I to Schedule III, including permit requirement changes. [Read More](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-designation/) Overview of the DEA’s placement of the synthetic cannabinoid CUMYL-PEGACLONE into Schedule I and its regulatory implications. [Explore Details](https://cedclinic.com/cumyl-pegaclone-schedule-i-designation/) [Medical THC and CBD formulation significantly reduces late-life dementia agitation](https://cedclinic.com/medical-thc-and-cbd-formulation-significantly-reduces-late-life-dementia-agitation/) Research findings on the efficacy of medical THC and CBD formulations in reducing agitation in late-life dementia patients. [Learn More](https://cedclinic.com/medical-thc-and-cbd-formulation-significantly-reduces-late-life-dementia-agitation/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).